Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab with Carboplatin in Metastatic TNBC
NCT03206203Phase 2Completed
- Sponsor
- Vanderbilt-Ingram Cancer Center
- Start
- Aug 2017
- Primary completion
- Nov 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab in triple-negative breast cancer (TNBC), sponsored by Vanderbilt-Ingram Cancer Center. Started Aug 2017; status: completed.
02
Drugs
atezolizumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03206203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03206203.